other material
confidence high
sentiment positive
materiality 0.75
Karyopharm reports Phase 1 selinexor+ruxolitinib data: 92% spleen response at week 24 in myelofibrosis
Karyopharm Therapeutics Inc.
- At week 24, 92% (11/12) evaluable patients achieved ≥35% spleen volume reduction (SVR35).
- Median spleen volume reduction of 45% at week 12 and 49% at week 24.
- 67% (4/6) evaluable patients achieved ≥50% symptom reduction (TSS50) at week 24.
- 57% (13/23) transfusion-independent patients maintained or improved hemoglobin levels.
- Common grade 3-4 AEs: anemia (37%) and thrombocytopenia (21%), both reversible.